Shares of CytomX Therapeutics Inc. (NASDAQ:CTMX) traded up 4.2% on Wednesday . The company traded as high as $10.43 and last traded at $10.42, with a volume of 155,833 shares traded. The stock had previously closed at $10.00.

A number of analysts recently weighed in on the stock. Zacks Investment Research lowered shares of CytomX Therapeutics from a “hold” rating to a “sell” rating in a research note on Wednesday, July 6th. Oppenheimer Holdings Inc. restated a “buy” rating on shares of CytomX Therapeutics in a research note on Tuesday, May 10th. One analyst has rated the stock with a sell rating and four have assigned a buy rating to the company’s stock. The company currently has an average rating of “Buy” and an average price target of $19.00.

The company’s 50-day moving average is $10.15 and its 200 day moving average is $12.17. The company’s market cap is $376.03 million.

CytomX Therapeutics (NASDAQ:CTMX) last posted its quarterly earnings results on Friday, May 6th. The company reported ($0.44) EPS for the quarter, missing the consensus estimate of ($0.26) by $0.18. Equities research analysts anticipate that CytomX Therapeutics Inc. will post ($1.61) EPS for the current fiscal year.

In other CytomX Therapeutics news, Director Timothy M. Shannon sold 51,343 shares of CytomX Therapeutics stock in a transaction dated Thursday, May 26th. The stock was sold at an average price of $10.34, for a total value of $530,886.62. Following the completion of the sale, the director now owns 134 shares in the company, valued at approximately $1,385.56. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, Director Ix L.P. Canaan sold 111,498 shares of CytomX Therapeutics stock in a transaction dated Tuesday, June 7th. The shares were sold at an average price of $10.01, for a total value of $1,116,094.98. The disclosure for this sale can be found here.

CytomX Therapeutics, Inc is an oncology-focused biopharmaceutical company. The Company is engaged in the development of a class of antibody therapeutics based on its Probody technology platform. It uses its platform to create cancer immunotherapies against clinically validated targets, as well as to develop cancer therapeutics against a range of targets.